Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date Manual Section Add/Remove/Modify Description
12/6/17 2028: Aplastic Anemia Pre-HCT Add Added the following instruction for question 31.
If this is a report of a second or subsequent transplant for aplastic anemia and this baseline disease insert has previously been completed for a prior transplant, indicate if the recipient received treatment for aplastic anemia between Day 0 of the previous HCT and the start of the preparative regimen for the subsequent HCT.
11/21/17 2010: AML Pre-Infusion Data Modify Corrected incorrect instruction provided for questions 6-9. The form asks for cytotoxic therapy; however, the manual incorrectly instructed centers to report any systemic therapies.
Systemic Cytotoxic Therapy: chemotherapy , immunotherapy, or targeted therapies delivered via the blood stream and distributed throughout the body. Therapy may be injected into a vein or given orally.
11/20/17 2100: Post-HCT Follow-Up Modify Added (in red) and removed (struck out) text from description of IPn / ARDS provided in the instructions for questions 441-485.
Interstitial pneumonitis / Acute respiratory distress syndrome (IPn/ARDS): IPn refers to inflammation of the alveolar walls. Acute respiratory distress syndrome typically refers to fluid build-up within the alveoli. In either case, gas exchange is impaired resulting in oxygen deprivation. Both conditions can result from infectious or non-infectious causes. Infectious causes may be bacterial, viral (CMV, adenovirus, RSV, influenza, etc.), or fungal. Only report IPn / ARDS resulting from non-infectious causes in questions 441-485.
11/20/17 2100: Post-HCT Follow-Up Add Added instructions below for question 158.
If the date of diagnosis is unknown, leave question 158 blank and override the validation error using the code “Unknown.” However, question 158 may not be left blank if treatment for acute GVHD (question 185) is reported “Yes.” If the exact clinical diagnosis date is unknown, but the treatment start date is known, report the date treatment started as the date of acute GVHD diagnosis.
11/15/17 4100: Cellular Therapy Essential Data Follow-Up Modify Replaced description of grade 4 organ toxicity provided in the instructions for Questions 82-138.
Grade 4 organ toxicity: As defined by the CTCAE criteria , grade 4 toxicity represents life-threatening consequences and urgent intervention is indicated Liver, lungs, heart, kidneys, gastrointestinal, musculoskeletal, neurologic, or other organ. Based on the CTC criteria
11/15/17 4000: Cellular Therapy Essential Data Pre-Infusion Modify Replaced instructions for question 35 as indicated below.
Indicate whether the cellular therapy product reported in this instance contains viral-specific Cytotoxic T Lymphocytes (CTLs). These products are generally from allogeneic donors that have been cultured / expanded and modified to treat specific viruses such as CMV, EBV, Adenovirus, etc.
Cytotoxic T lymphocytes (CTLs) are a type of white blood cell that can kill foreign cells, cancer cells, and cells infected with a virus. Indicate “yes” or “no” for the donor being reported in this instance and continue with question 36.
11/15/17 2100: Post-HCT Follow-Up Add Added the fungal infection codes below to the list of infections which will prompt the Fungal Infection Post-HCT Form to come due. The list is provided in the instructions for questions 428-436.
  • 270 Blastomyces (dermatitidis)
  • 201 Candida albicans
  • 208 Candida non-albicans
  • 222 Cryptococcus gattii
  • 221 Cryptococcus neoformans
  • 261 Histoplamsa (capsulatum)
  • 272 Scedosporium (all species)
  • 503 Suspected fungal infection


Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.

Post your comment on this topic.

Please do not use this for support questions.
For customer support, please contact us here.

Post Comment